HC Wainwright & Co. initiates coverage of Monte Rosa Therapeutics with a Buy rating
Published . Updated .
Fintel reports that on October 1, 2026, HC Wainwright & Co. initiated coverage of Monte Rosa Therapeutics (NASDAQGS:GLUE) with a Buy recommendation.Prior to this rating action, the stock's pre-action close was $11.93 on September 30, 2026. This close represents a one-week pri
Directly affected
- GLUE Monte Rosa Therapeutics
Named in this report.
Indirectly affected
- UPGD INVESCO BLOOMBERG ANALYST RATING ETF
GA selected UPGD as a RELATED security because its canonical security name directly matches this event's themes: rating. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Fintel reports that on October 1, 2026, HC Wainwright & Co. initiated coverage of Monte Rosa Therapeutics (NASDAQGS:GLUE) with a Buy recommendation.Prior to this rating action, the stock's pre-action close was $11.93 on September 30, 2026.…
Source: Nasdaq Markets
How far Monte Rosa Therapeutics (GLUE) has moved since 1 Oct 2026
Since the first closing price after “HC Wainwright & Co. initiates coverage of Monte Rosa Therapeutics with a Buy rating,” Monte Rosa Therapeutics (GLUE) is +1.62%. The S&P 500 fund (SPY) is -0.40% over the same days, a +2.02% difference versus the market.
Who gains and who loses around Monte Rosa Therapeutics (GLUE)
Companies carried with this story
- GLUE Monte Rosa Therapeutics
Monte Rosa Therapeutics (GLUE) is linked, with no stored direction, medium confidence in the 1 Oct 2026 story “HC Wainwright & Co. initiates coverage of Monte Rosa Therapeutics with a Buy rating.” Reason on file: GA selected GLUE as a RELATED security because its canonical security name directly matches this event's themes: therapeutics, monte, rosa. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- UPGD Invesco Bloomberg Analyst Rating Etf
In “HC Wainwright & Co. initiates coverage of Monte Rosa Therapeutics with a Buy rating,” Invesco Bloomberg Analyst Rating Etf (UPGD) is linked, with no stored direction, medium confidence. Reason on file: GA selected UPGD as a RELATED security because its canonical security name directly matches this event's themes: rating. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Monte Rosa Therapeutics (GLUE)
“HC Wainwright & Co. initiates coverage of Monte Rosa Therapeutics with a Buy rating” (1 Oct 2026) reaches Monte Rosa Therapeutics (GLUE) through this story.
What ties Monte Rosa Therapeutics (GLUE) to the headline is this: GA selected GLUE as a RELATED security because its canonical security name directly matches this event's themes: therapeutics, monte, rosa. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Invesco Bloomberg Analyst Rating Etf (UPGD) is here too. Its reason reads: GA selected UPGD as a RELATED security because its canonical security name directly matches this event's themes: rating. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
The price range for Monte Rosa Therapeutics (GLUE), and the dates in the story
GLUE traded between 9.71 and 14.38 across 19 sessions. The latest close on file is 10.66. UPGD traded between 80.14 and 82.00 across 17 sessions. The latest close on file is 82.00.
A simple score for Monte Rosa Therapeutics (GLUE)
21 out of 100
“HC Wainwright & Co. initiates coverage of Monte Rosa Therapeutics with a Buy rating” scores 21 out of 100. The score uses 1 sources, and 2 linked companies.